The ability to accurately and efficiently distinguish between benign blood pressure increases in pregnancy and pre-eclampsia is a highly desired capability for maternity care providers. In tandem, the ability to effectively detect the small fetus at risk of preventable morbidity or death from FGR is equally important. Since both issues have a common placental origin, it is unsurprising that the measurement of these so-called angiogenic growth factors in clinical practice is both highly valuable to confidently exclude pre-eclampsia and to detect true placental FGR. 7 In The Lancet, Kate Duhig and colleagues 8 from the PARROT trial group report their findings of a stepped-wedge cluster-randomised controlled trial of PlGF testing. Over a 16-month period, they tested 1035 women with suspected pre-eclampsia for their circulating PIGF concentrations, and they either revealed the results (alongside the use of a clinical management algorithm) or concealed them from doctors and patients. The study was conducted in the high-resource setting of 11 large maternity units in the UK, which were each responsible for 3000-9000 deliveries per year. The investigators chose the time from presentation with suspected pre-eclampsia to documented pre-eclampsia as their primary outcome, which was shorter by a median of 2·2 days among women in whom PlGF data were revealed versus those in whom these data were concealed. In this high-resource setting, it is perhaps unsurprising that the incidence of predefined severe adverse events was low, that this incidence was slightly reduced in the group in which PlGF data were disclosed (from 5% to 4%; adjusted odds ratio 0·32, 95% CI 0·11-0·96; p=0·043), and that no maternal deaths occurred. The authors were rightly concerned that PlGF testing could result in more iatrogenic preterm births and, hence, they incorporated training in use of a clinical management algorithm with testing, such that this issue was no longer of concern. No significant change was observed in neonatal outcomes.
In the context of this high-resource setting, several findings of the secondary outcome measures deserve attention. First, four women had either eclampsia or a stroke in the concealed testing group (all with low PlGF), whereas none did in the revealed group. However, the significant difference observed in maternal severe adverse events (5% in concealed testing vs 4% in revealed testing) is possibly the consequence of the lower prevalence of blood product transfusion (3·1% vs 1·6%), which is not necessarily related to severe peripartum bleeding or long-term complications. Severe umbilical artery Doppler abnormalities were found before delivery in 5-10% of enrolled women, indicating established placental vascular disease, yet one in four women had no ultrasound assessment before delivery. Therefore, future research should focus on the potential role of ultrasound to optimise delivery timing and thereby reduce this risk of perinatal death or severe morbidity.
Duhig and colleagues are to be strongly commended for their efforts to advance the care of women at risk of maternal and perinatal harm from diseases largely arising within the placenta, which can be robustly identified using the PlGF blood test. Future largescale studies need to confirm the effects of its use on severe maternal adverse events and to determine the usefulness of the addition of sFLT-1 testing, especially for the prompt identification of women at risk of organspecific injury beyond their placenta. 
Pembrolizumab for all PD-L1-positive NSCLC
Before the introduction of immune checkpoint inhibition therapy targeting programmed death protein 1 (PD-1) ligand (PD-L1), either given as single agent or in combination with chemotherapy, advanced non-small-cell lung cancer was uniformly fatal. These drugs have changed the treatment landscape for advanced non-small-cell lung cancer. Long-term results from studies of single-agent nivolumab 1 and pembrolizumab 2 have shown disease control in approximately 15% of unselected patients. In the pivotal KEYNOTE-024 study, 3 treatment-naive patients with metastatic non-small-cell lung cancer and a PD-L1 tumour proportion score (TPS) of 50% or greater were randomly assigned to receive either pembrolizumab as monotherapy or platinum-doublet chemotherapy. Progression-free survival and overall survival favoured the pembrolizumab group. Subsequently, after approval by the US Food and Drug Administration and the European Medicines Agency, single-agent pembrolizumab became standard of care for patients with advanced non-small-cell lung cancer and a PD-L1 TPS greater than 50%.
In The Lancet, Tony Mok and colleagues 4 present the KEYNOTE-042 study, which adds another piece to the puzzle of defining the optimum first-line treatment for advanced non-small-cell lung cancer. They investigated whether first-line pembrolizumab monotherapy could be extended to patients with PD-L1 TPS of 1% of greater. This approach defied hazard given that a in similar phase 3 trial firstline nivolumab had failed against chemotherapy. 5 1274 patients (902 men and 372 women, mean age 63 years [IQR 57-69]) were randomly assigned to receive pembrolizumab or platinum-doublet chemotherapy. The primary endpoint was overall survival in three populations of patients: those with PD-L1 TPS of 50% or greater, 20% or greater, and 1% or greater. Overall survival was better in the pembrolizumab group than in the chemotherapy group in all three populations (TPS ≥50% median 20·0 months, 95% CI 15·4-24·9, vs 12·2 months, 10·4-14·2; TPS ≥20% 17·7 months, 15·3-22·1, vs 13·0 months, 11·6-15·3; and TPS ≥1% 16·7 months, 13·9-19·7, vs 12·1 months, 11·3-13·3). Not unexpectedly, the magnitude of overall
